<code id='2CB4B54DBA'></code><style id='2CB4B54DBA'></style>
    • <acronym id='2CB4B54DBA'></acronym>
      <center id='2CB4B54DBA'><center id='2CB4B54DBA'><tfoot id='2CB4B54DBA'></tfoot></center><abbr id='2CB4B54DBA'><dir id='2CB4B54DBA'><tfoot id='2CB4B54DBA'></tfoot><noframes id='2CB4B54DBA'>

    • <optgroup id='2CB4B54DBA'><strike id='2CB4B54DBA'><sup id='2CB4B54DBA'></sup></strike><code id='2CB4B54DBA'></code></optgroup>
        1. <b id='2CB4B54DBA'><label id='2CB4B54DBA'><select id='2CB4B54DBA'><dt id='2CB4B54DBA'><span id='2CB4B54DBA'></span></dt></select></label></b><u id='2CB4B54DBA'></u>
          <i id='2CB4B54DBA'><strike id='2CB4B54DBA'><tt id='2CB4B54DBA'><pre id='2CB4B54DBA'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:hotspot    Page View:2
          ASH19 CAR-T
          Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

          The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

          That sounds staggering to many patients — but it’s far less than analysts expected.

          advertisement

          The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          BIO selects John Crowley as new CEO
          BIO selects John Crowley as new CEO

          JohnCrowleypicturedwithhisdaughterMegan.CrowleyfamilyWASHINGTON— TheBiotechnologyInnovationOrganizat

          read more
          Tori Bowie and the unacceptable rates of Black maternal death
          Tori Bowie and the unacceptable rates of Black maternal death

          AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

          read more

          J&J lung cancer data amount to new salvo against AstraZeneca

          TheJohnson&JohnsonboothatESMO2023.AndrewJoseph/STATMADRID—Acompetitionhasbeenbrewingbetweentwoph